2019
Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms
Patel SS, Ho C, Ptashkin RN, Sadigh S, Bagg A, Geyer JT, Xu ML, Prebet T, Mason EF, Seegmiller AC, Morgan EA, Steensma DP, Winer ES, Wong WJ, Hasserjian RP, Weinberg OK. Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. Blood Advances 2019, 3: 1540-1545. PMID: 31085507, PMCID: PMC6517660, DOI: 10.1182/bloodadvances.2019000090.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AFemaleHumansMaleMiddle AgedMutationMyelodysplastic SyndromesNuclear ProteinsNucleophosminPrognosisProportional Hazards ModelsProtein Tyrosine Phosphatase, Non-Receptor Type 11Survival RateTumor Suppressor Protein p53ConceptsMyelodysplastic syndromeMyeloid neoplasmsDe novo acute myeloid leukemia (AML) patientsNovo acute myeloid leukemia patientsAcute myeloid leukemia patientsBone marrow blastsAggressive clinical courseStem cell transplantLimited case seriesShorter overall survivalMyeloid leukemia patientsIntensive therapeutic regimensTotal mutation countsMarrow blastsOverall survivalClinical courseCase seriesCell transplantMultivariable analysisTherapeutic regimensLeukemia patientsLarge cohortYounger agePatientsNormal karyotype
2013
Cytotoxic and Gamma-Delta Subtypes Of Peripheral T-Cell Lymphoma: A Single Center Experience
Fraser J, Subtil A, Alpdogan O, Seropian S, Cooper D, Xu M, Foss F. Cytotoxic and Gamma-Delta Subtypes Of Peripheral T-Cell Lymphoma: A Single Center Experience. Blood 2013, 122: 5092. DOI: 10.1182/blood.v122.21.5092.5092.Peer-Reviewed Original ResearchGamma-delta T-cell lymphomaT-cell lymphomaCutaneous gamma-delta T-cell lymphomaHepatosplenic T-cell lymphomaPeripheral T-cell lymphomaStem cell transplantationInitial therapyCell transplantationLymphoid neoplasmsPrimary cutaneous gamma-delta T-cell lymphomaGamma delta T-cell receptorInitiation of chemotherapySingle-center experienceAggressive clinical courseOff-label useT-cell NHLT cell receptorAdvisory CommitteeAcute GVHDAlloBMT patientsMedian followSalvage therapyAdditional therapyB symptomsFirst remission